Regarding the cytotoxicity assay, trastuzumab(MMAE)2 shows high potency in SK-BR-3 (HER2 high) breast cancer cells, with a half maximal effective concentration (EC50) of 55 ± 10 pM (Figure 4d). Here, ERBB2 is linked to breast carcinoma.